+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy



Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy



Maturitas 59(4): 387-393



There is a need to evaluate the extent of endometrial pathologies that might develop in postmenopausal breast cancer patients following discontinuation of tamoxifen (TAM) therapy. The medical records of 153 postmenopausal breast cancer patients who remained untreated following discontinuation of tamoxifen therapy were evaluated for various clinical features, for endometrial thickness measurements, as detected by transvaginal ultrasonography, and for various endometrial pathologies detected. The last endometrial thickness measurement performed before discontinuation of tamoxifen was compared with endometrial thickness measured following discontinuation of tamoxifen. Patients were followed for 37.5+/-31.3 months. There was a gradual and significant decrement of endometrial thickness measured at the last ultrasonographic study performed before cessation of tamoxifen, compared to that observed in all four ultrasonographic studies performed following discontinuation of tamoxifen (P=0.001). Endometrial thickness gradually and significantly decreased in correlation with the time intervals of the four ultrasonographic studies performed following discontinuation of tamoxifen (P=0.001). Overall, 40 hysteroscopies were performed in 38 (24.8%) patients. No tissue was obtained in 18 (11.8%) patients. Overall endometrial pathologies were diagnosed in 22 (14.4%) patients. Benign endometrial polyps were the most frequent endometrial pathology recovered: 17 (11.1%) patients. No endometrial malignancy was diagnosed. The rate of endometrial pathologies considerably decreased with the extension of time following discontinuation of tamoxifen therapy. Long-term follow-up of postmenopausal breast cancer patients who remained untreated following discontinuation of TAM therapy did not reveal any malignant endometrial pathology. Only few benign endometrial pathologies were diagnosed, which became fewer in time.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 032191651

Download citation: RISBibTeXText

PMID: 18490117

DOI: 10.1016/j.maturitas.2008.04.001


Related references

Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. Breast Cancer Research and Treatment 148(2): 337-343, 2014

Long-term transvaginal ultrasonographic endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment. Gynecologic Oncology 74(2): 222-226, 1999

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncologica 46(2): 133-145, 2007

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. Acta Oncologica: 1-5, 2017

Endocrinology of adjuvant chemotherapy and long term tamoxifen therapy in premenopausal and postmenopausal node positive breast cancer patients. Breast Cancer Research & Treatment 6(2): 183, 1985

Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. European Journal of Gynaecological Oncology 25(3): 321-323, 2004

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Research and Treatment 89(2): 135-143, 2005

Simple ovarian cysts in postmenopausal patients with breast carcinoma treated with tamoxifen: long-term follow-up. Radiology 227(3): 844-848, 2003

Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 7(6): 335-339, 1998

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology 37(2): 105-114, 2019

Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up. Journal of Laboratory and Clinical Medicine 109(3): 300-307, 1987

Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Bjog 107(9): 1083-1087, 2000

Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecologic Oncology 55(3 Pt 1): 410-414, 1994

Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. Acta Oncologica 45(5): 517-527, 2006

Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients short and long term endocrine effects. Breast Cancer Research & Treatment 10(2): 201-204, 1987